The U.S. Court of Appeals for the Federal Circuit has ruled that Harvard-affiliated Broad Institute can keep its patents on gene-editing technology CRISPR. The court rejected the argument that the work was already covered by patents owned by the University of California at Berkeley. Companies developing CRISPR-based therapies include Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Crispr Therapeutics (CRSP).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.